cbai cannot afford to buy ccel Portnoy is an idea of what he wants to do. Marketing for Q1 was cut the price for the cord blood service is around 1700 versus 999-1400. So this Q will show how this approach worked out for ccel. Second, ccel was sitting on a large amount of cash and still it. Portnoy closed one of the RSA for 2.3mil. This will reduce the sharing of revenue for the sales in New York for the entire year. Q1 will show a lower "interest expense" and it will occur for the entire year. CCEL had raised cash by selling rights in the storage renewal at 50% (instead of selling stocks and killing the shareholders), and not they are looking to close it. RSA costs last year were around 1.4 mil if ccel closes it all, profits go up by 1.4mil. Research agreements, ccel has leverage. S-evans is the china partner for ccel using stem cells from menstrual blood.
Plus low float, high insider ownership (Portnoy bought recently at around 2 buck, unlike Matt spending 300 bucks to buy shares) Insider Transactions Reported - Last Two Years Date Insider Shares Type Transaction Value* Feb 28, 2012 WHEELER JONATHAN H. Director 25,000 Direct Purchase at $2 per share. 50,000 Feb 28, 2012 PORTNOY DAVID Officer 18,000 Direct Purchase at $2 per share. 36,000
Clap...Clap..Clap ~ DD does wonders : ) This may help also.
Been buying CBAI ever since the Portnoys took over the CCEL board.
I like the odds the rockets about to blast off. I hope there is a least a hint in the filing.
AIMHO GLTY
------------------------------------------------------------------ SHOULD YOU RELY ON THE MANAGEMENT SLATE TO MAXIMIZE VALUE?
Cryo-Cell recently announced that the Executive Committee of its Board of Directors has authorized the Company's management and financial advisors to explore strategic alternatives to enhance stockholder value, including a possible sale of the Company. Having invested significant percentages of our personal financial resources in Cryo-Cell, we believe that our interests in Cryo-Cell are the same as yours and we are asking ourselves if the timing of this recent announcement is a mere coincidence given the rapidly approaching election?
In evaluating incumbent management’s credibility and commitment to exploring a sale of the Company, please be aware that in 2010, when I introduced DW Healthcare Partners, a private equity healthcare firm, to discuss acquiring Cryo-Cell, Cryo-Cell not only rebuffed DW Healthcare’s offer, but Cryo-Cell’s board of directors refused to even enter into negotiations. We believe DW Healthcare’s publicly issued press release over the PRNewswire on October 15, 2010 said it all:
“[Cryo-Cell’s] board's refusal to engage in discussions regarding our offer raises serious concerns about the board's priorities.” ??-----------------------------------------------------------------
Please see the full press release at: http://www.redorbit.com/news/health/1932351/dwhp_withdraws_second_offer_for_ccel__based_on_boards/. ------------------------------------------------------------------ Furthermore, three members of our slate have backgrounds in investment banking. We believe we are clearly qualified to evaluate the best strategic alternatives for Cryo-Cell, and will do so with the mutual interests of all Cryo-Cell stockholders in mind.
News 
Market Data 
Discover 
AI
